The market continues to stress the company's exposure to OpenAI, not least as Oracle's debt continues to balloon while its cash flow goes in the other direction.

Building a sustainably profitable biotech company from scratch and advancing innovative medicines to patients is no easy task. The lessons from our industry's pioneers teach us that this effort ...